Jupiter Neurosciences, Inc. (JUNS) stock
Close on Nov 12, 2026Market cap $1.43MP/E –Yield –
Jupiter Neurosciences, Inc. reported revenue of $21.80K for fiscal 2025. At the latest close the market valued the company at $1.43M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $1.43M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $21.80K
- Net income
- -$9.20M
- EPS, diluted
- -$18.89
- Book value per share
- -$0.66
- Diluted shares
- 1M
Trading
- Previous close
- $2.14
- Open
- $2.13
- Day's range
- $1.78 – $2.34
- Volume
- 45,360
- Average volume (20 days)
- 18,975
- 52-week range
- $1.78 – $103.53
- RSI (14 days)
- 33.1
- Volatility (1 year)
- 122.1%
- Relative volume
- 0.06×
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | JUNS | S&P 500 | Difference | JUNS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -38.8% | -2.7% | −36.1 pts | ||
| 3 months | -59.7% | -1.7% | −57.9 pts | ||
| Year to date | -97.6% | +11.9% | −109.5 pts | ||
| 1 year | -98.2% | +12.0% | −110.2 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Jupiter Neurosciences filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- Update
- Update
- News
About Jupiter Neurosciences
Pharmaceutical Preparations
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company focused on developing treatments that utilize an enhanced oral resveratrol formulation to address neuroinflammation, central nervous system disorders, and rare diseases. Its proprietary platform product, JOTROL, delivers resveratrol using micellar technology designed to enhance absorption and bioavailability. The company operates through two main business segments: pharmaceutical operations targeting therapeutic indications such as Parkinson's disease, and consumer products consisting of premium nutritional supplements sold under the Nugevia brand name. The initial Nugevia wellness product line comprises three formulations—GLO, MND, and PWR—marketed directly to consumers for cellular health, cognitive support, and mitochondrial performance.
Company profile, executives and historyJupiter Neurosciences stock: common questions
What is Jupiter Neurosciences's stock price?
JUNS closed at $1.86 on Nov 12, 2026, down 13.08% on the day. Over the past 52 weeks it traded between $1.78 and $103.53.
What is Jupiter Neurosciences's market cap?
Jupiter Neurosciences was worth $1.43M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is JUNS's P/E ratio?
Jupiter Neurosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$18.89), so it has no meaningful P/E ratio.
How much revenue does Jupiter Neurosciences make?
Jupiter Neurosciences reported revenue of $21.80K for fiscal 2025.
Does Jupiter Neurosciences pay a dividend?
No. Jupiter Neurosciences has not paid a cash dividend over the last twelve months.
How has JUNS stock performed over the past year?
Including dividends, JUNS returned -98.2% over the past year, against +12.0% for the S&P 500.
Who are Jupiter Neurosciences's competitors?
Companies most similar to Jupiter Neurosciences by business, industry and size include KPRX, BDPT, ADXN, CRVO, PRFX.
See a number that looks wrong?